Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in primary immune thrombocytopenia
NCT04188379Phase 3Completed
- Sponsor
- argenx
- Start
- Dec 2019
- Primary completion
- Feb 2022
- Modality
- Antibody Fragments
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in primary immune thrombocytopenia (ITP) comparing Efgartigimod Arm with Placebo Arm (2 arms). Primary endpoint: Percentage of Participants With Chronic ITP With a Sustained Platelet Count Response. Started Dec 2019; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04188379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188379.